I was constantly sweating." She was also retaining fluid. Elsie soon learned the cause - cardiac amyloidosis. "We used to think of it more as a rare disease," says Dr. Carly Fabrizio of Temple Health.

Measurements of the curvature of the cornea of the eye can be significantly affected by the status of dry eye in a patient, according to a study published in Frontiers in Medicine. 1 Different ...

A corneal ulcer is an open sore or wound on the cornea — the transparent, dome-shaped surface that covers the front of the eye and focuses light into it. Often beginning as keratitis ...

The Food and Drug Administration (FDA) has granted Fast Track designation to urcosimod for the treatment of neuropathic corneal pain. Neuropathic corneal pain is a condition that results in pain ...

The human transforming growth factor β-induced protein (TGFBIp) is involved in several types of corneal dystrophies where protein aggregation and amyloid fibril formation severely impair vision. Most ...

Amyloidosis is a group of conditions that cause an abnormal protein called amyloid to build up in the body. Treatment depends on the type of amyloidosis but may include medications and organ ...

The investigational treatment is currently being evaluated in a 3-part phase 1 trial (ClinicalTrials.gov Identifier: NCT05521022) in adult patients with systemic amyloidosis, as well as a phase 2 ...

DEAR MAYO CLINIC: My dad was diagnosed with cardiac amyloidosis shortly after his 70th birthday. It’s difficult to pronounce let alone understand. What is cardiac amyloidosis? Am I at risk ...

Amyloid heart disease occurs when faulty proteins build up in the heart, making it more difficult for the heart to pump blood around the body. Learn more about it here.

Wainua is an injectable medicine. Here’s how it treats hereditary transthyretin-mediated amyloidosis (hATTR).

In people with a rare condition called light chain amyloidosis, light chain proteins—which are a component of antibodies—mutate and build up in different organs. In new research published in ...

During this double-blind period, the primary endpoint was reduced with vutrisiran by 28% in the overall population (hazard ratio [HR], 0.718; P = .0118) and by 33% in the 395-patient monotherapy ...